Cure8 research brief
Blood-based inflammatory ratios like CRP/albumin were associated with higher odds of needing anti‑TNF therapy, colectomy, and longer hospital stays in moderate–severe UC, suggesting potential utility as complementary noninvasive markers.
Clinicians treating moderate–severe ulcerative colitis; researchers in IBD biomarkers; adult patients interested in noninvasive monitoring.
This retrospective study of 106 patients with moderate to severe ulcerative colitis (April 2017–August 2023) evaluated the C-reactive protein/albumin ratio (CAR) and other inflammatory ratios as noninvasive biomarkers.
Higher CAR, CRP, and some blood-count–derived ratios were associated with greater odds of needing anti‑TNF therapy, higher odds of colectomy, and longer hospital stay. The authors conclude CAR may be a complementary marker but note predictive performance was modest.
Results come from a retrospective single‑center cohort (n=106) and the authors report modest predictive performance; they call for multicenter prospective studies before clinical adoption.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
